NSCLC: Immunotherapy Beyond Progression – OncLive
|
NSCLC: Immunotherapy Beyond Progression
OncLive Benjamin Besse, MD, PhD: I think treatment beyond progression is not an issue of immunotherapy, it's a general concern. It may be a good strategy with some TKIs, sometimes with chemotherapy, and with immunotherapy. It's always the same. There is not 1 … |
